JPRN-UMIN000000976已完成1 期
Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide for Patients with Oral Cancer - Phase I Clinical Study of Survivin-2B Peptide Vaccine Therapy
Department of Oral Surgery, Sapporo Medical University School of Medicine0 个研究点目标入组 10 人开始时间: 2008年1月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) prior cancer therapy, such as chemotherapy, radiation therapy, steroid therapy, or other immunotherapy within the past 4 weeks, 2) presence of other cancers that might influence the prognosis, 3) immunodeficiency or a history of splenectomy, 4) severe cadiac insufficiency, acute infection, or hematopoietic failure, 5) ongoing brest-feeding, 6) unsuitability for the trial based on clinical judgement.
研究者
相似试验
已完成
1 期
Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide Combined with IFA and IFN-alpha for Patients with Urothelial Cancer (Phase I clinical study)JPRN-UMIN000005859Department of Urology, Sapporo Medical University School of Medicine15
未知
1 期
Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide Mixed with IFA, IFA and IFN-alpha, IFA and IL-2, or IFA and GM-CSF for Patients with Digestive Cancer and Endocrine Organic Cancer (Phase I clinical study)Advanced or recurrent digestive cancer and Endocrine Organic CancerJPRN-UMIN000000905Department of Surgery, Sapporo Medical University School of Medicine108
已完成
1 期
Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide for Patients with Urothelial Cancer (Phase I clinical study)Advanced or recurrent urothelial cancerJPRN-UMIN000001499Department of Urology, Sapporo Medical University School of Medicine12
已完成
1 期
Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide for Patients with Colorectal Cancer and Breast CancerAdvanced or recurrent colorectal cancer and breast cancerJPRN-UMIN000000902Department of Surgery, Sapporo Medical University School of Medicine30
已完成
1 期
Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide Mixed with IFA and IFN-alpha for Patients with Oral Cancer (Phase I clinical study)Advanced or recurrent oral cancerJPRN-UMIN000000999Department of Oral Surgery, Sapporo Medical University School of Medicine7